Feb 2, 2026 06:50AM H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)

Jan 20, 2026 08:04AM Coya Therapeutics CEO outlines 2026 priorities in stockholder letter

Jan 8, 2026 08:02AM Coya Therapeutics reports positive results from frontotemporal dementia study

Jan 5, 2026 08:03AM FDA accepts Coya Therapeutics IND for dementia treatment COYA 302

Jan 5, 2026 06:42AM H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)

Dec 23, 2025 08:01AM Coya Therapeutics receives Health Canada approval for ALS trial expansion

Dec 11, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)

Nov 24, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)

Nov 12, 2025 04:35PM Coya Therapeutics, Inc. (COYA) Tops Q3 EPS by 46c

Nov 4, 2025 08:01AM Coya Therapeutics reports positive results for inflammation drug candidate

Oct 14, 2025 10:55AM Coya Therapeutics (COYA) Shares Up As Greenlight Says It's The Largest Shareholder - Bloomberg

Sep 29, 2025 08:02AM Coya Therapeutics completes enrollment in frontotemporal dementia study

Sep 23, 2025 06:38AM H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)

Sep 22, 2025 09:50AM Lucid Capital Markets Reiterates Buy Rating on Coya Therapeutics (COYA), PT $20

Sep 16, 2025 08:01AM Coya Therapeutics reports positive preclinical results for COYA 303

Sep 4, 2025 08:03AM COYA Therapeutics ALS trial accepted by NEALS research consortium

Aug 25, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)

Aug 25, 2025 05:22AM BTIG Reiterates Buy Rating on Coya Therapeutics (COYA)

Aug 12, 2025 08:37AM Coya Therapeutics (COYA) Files $75M Mixed Shelf

Aug 12, 2025 08:03AM Coya Therapeutics, Inc. (COYA) Misses Q2 EPS by 49c

Jul 24, 2025 08:15AM Coya Therapeutics publishes research linking inflammation to Parkinson's disease

Jul 9, 2025 08:48AM Lake Street Capital Markets Starts Coya Therapeutics (COYA) at Buy

Jun 9, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)

Jun 9, 2025 06:05AM Lucid Capital Markets Starts Coya Therapeutics (COYA) at Buy

Jun 2, 2025 08:02AM Coya Therapeutics (COYA) Issues New US Patent Protecting Methods of Producing Recombinant Human Interleukin-2 Liquid Formulations

May 13, 2025 04:08PM BTIG Reiterates Buy Rating on Coya Therapeutics (COYA)

May 13, 2025 08:02AM Coya Therapeutics, Inc. (COYA) Tops Q1 EPS by 2c

Apr 24, 2025 08:15AM Coya Therapeutics (COYA) Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate F

Apr 21, 2025 09:52AM Coya Therapeutics (COYA) publicizes results of of COYA 303 study

Apr 17, 2025 07:02AM Atea Pharmaceuticals (AVIR) Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Mar 26, 2025 08:15AM Coya Therapeutics (COYA) Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Mar 20, 2025 05:05AM BTIG Reiterates Buy Rating on Coya Therapeutics (COYA)

Feb 6, 2025 12:38PM BTIG Reiterates Buy Rating on Coya Therapeutics (COYA)

Feb 6, 2025 08:00AM Coya Therapeutics (COYA) Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Support

Jan 21, 2025 08:15AM Coya Therapeutics (COYA) Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Dec 18, 2024 08:16AM Coya Therapeutics (COYA) Provides Enrollment Update of Phase 1 Study of Low Dose Interleukin-2 + CTLA4-Ig Fusion Protein

Dec 4, 2024 07:05AM D. Boral Capital Starts Coya Therapeutics (COYA) at Buy, PT $15

Nov 19, 2024 08:15AM Coya Therapeutics (COYA) CEO Issues Letter to Stockholders

Nov 6, 2024 08:02AM Coya Therapeutics, Inc. (COYA) Tops Q3 EPS by 10c

Nov 1, 2024 08:16AM Coya Therapeutics (COYA) Appoints Arun Swaminathan as CEO

Oct 29, 2024 06:32AM Coya Therapeutics (COYA) Reports Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2

Oct 22, 2024 09:02AM Coya Therapeutics (COYA) Announces 1.38M Share Offering at $7.25/sh

Sep 16, 2024 08:15AM Coya Therapeutics (COYA) Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease

Aug 19, 2024 09:00AM Coya Therapeutics (COYA) Appoints Arun Swaminathan as Next CEO

Aug 12, 2024 08:02AM Coya Therapeutics, Inc. (COYA) Misses Q2 EPS by 42c

Aug 2, 2024 08:16AM Coya Therapeutics (COYA) Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29,

Jul 31, 2024 08:15AM Coya Therapeutics (COYA) Files for New U.S. Patents for COYA 301 in Combination with GLP-1 Receptor

Jun 20, 2024 08:16AM Coya Therapeutics (COYA) Expands Sponsored Research Collaboration with Houston Methodist Research Institute

Jun 11, 2024 08:15AM Coya Therapeutics (COYA) Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology